While tirzepatide has bagged FDA approval for treating T2D and for weight loss, the critical question remains can it also safeguard the kidneys, a key objective in diabetes care?
Based on a completed data review, the agency concluded that denosumab increases the risk for severe hypocalcemia in patients with chronic kidney disease.
Fifteen percent of Americans have chronic kidney disease, so why do only 10% know about it? Primary care clinicians can and should be doing more to identify patients.
Gestational diabetes raises the risk for future chronic kidney disease, a risk heightened by subsequent diabetes or hypertension, found an analysis of Danish registry data.
A new study explores if the kidney failure risk equation can identify patients with type 2 diabetes who would show renal improvement with intensive glycemic management.